Original Research
Accepted on 15 Aug 2025
Real-world data on adult AML with FLT3-ITD mutation from the Thai Acute Leukemia Working Group (TALWG)
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1606943
Type at least 3 characters
1,900 articles
Case Report
Accepted on 14 Aug 2025
Erdheim-Chester Disease: Unveiling Hidden Manifestations through Two Case Reports
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1611907
Case Report
Accepted on 14 Aug 2025
Case Report: Transformation of Natural Killer-cell Large Granular Lymphocytic Leukemia (NK-LGLL) to Aggressive Natural Killer Cell Leukemia (ANKL)
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1648711
Case Report
Published on 13 Aug 2025
Case Report: Simnotrelvir/Ritonavir are effective in shortening the course of prolonged SARS-CoV-2 infection during anti-CD20 maintenance therapy in patients with follicular lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1583932
- 375 views
Original Research
Published on 13 Aug 2025
Implementing comprehensive geriatric assessment in an academic hematologic outpatient setting: experiences from medical doctors and patients
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1570889
- 239 views
Original Research
Published on 13 Aug 2025
Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1627175
- 433 views
Case Report
Published on 13 Aug 2025
Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1596256
- 306 views
Brief Research Report
Accepted on 12 Aug 2025
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: Analysis of the GIMEMA-SUSTRENIM trial
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1645217
Original Research
Published on 12 Aug 2025
Development and validation of a machine learning-based early warning system for predicting venous thromboembolism risk in hospitalized lymphoma patients undergoing chemotherapy: a multicenter and retrospective cohort study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1566905
- 601 views
Case Report
Accepted on 11 Aug 2025
Successful CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation in a secondary central nervous system lymphoma patient with COVID-19 infection: A case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1656034
- 121 views
Original Research
Accepted on 11 Aug 2025
Soluble B-cell Maturation Antigen as a Serum Marker of MRD in Patients with Multiple Myeloma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1631511
Original Research
Accepted on 08 Aug 2025
A case report of TBL1XR1-RARB positive pediatric acute promyelocytic leukemia and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1566404
- 106 views
Case Report
Published on 08 Aug 2025
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1644661
- 528 views
Original Research
Accepted on 06 Aug 2025
Real-World Cardiovascular Risks of Ibrutinib in Chronic Lymphocytic Leukemia: A Retrospective Study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1624761
- 132 views
Original Research
Accepted on 06 Aug 2025
Risk of hematological malignancies and anticipation in the families of patients with non-Hodgkin and Hodgkin lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1639819
- 129 views
Case Report
Published on 06 Aug 2025
Case Report: Reactive T-cell large granular lymphocytes in the bone marrow of a patient with relapsed/refractory multiple myeloma receiving teclistamab
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1630929
- 448 views